CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 43 target
Drug / intervention
Intensity Modulated Radiation Therapy (IMRT) +1 moreradiation
Likely dose
Not stated in record
Key inclusion· 8
  • ✓Pathologically confirmed high-grade (grade 2 or 3) soft tissue sarcoma of deep trunk and/or extremity
  • ✓Primary site deemed resectable prior to trial start
  • ✓AJCC 8th edition staging T1-4 N0 M0, no distant metastases
  • ✓Measurable disease at primary site clinically or radiographically evident
Key exclusion· 6
  • ✕Contraindications to MRI
  • ✕Positive urine pregnancy test
  • ✕Gross total excision of primary STS, including unplanned excision
  • ✕Superficial sarcoma in subcutaneous or cutaneous tissue

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05301283
NCT05301283Phase 2RecruitingOn TrackUpdated 6mo ago
Long Recruiting
CompareCT.gov

Phase 2 Clinical Trial of Radiomic Habitat-Directed Radiation Dose Escalation for High-Grade Soft Tissue Sarcoma

H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted Mar 29, 2022·Updated Dec 4, 2025

In Brief

A Phase 2 clinical trial evaluating Intensity Modulated Radiation Therapy (IMRT) and MRI for High Grade Sarcoma. Currently recruiting, targeting 43 participants across 1 site.

Detailed Summary

The purpose of the study is to utilize radiomic images to precisely locate areas of tumor that can be treated with dose escalation radiation therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHigh Grade Sarcoma
CountriesUnited States
CollaboratorsViewray Inc.

Timeline

Phase 2Recruiting
2023202420252026
First PostedMar 29, 2022
Enrollment StartMay 18, 2022
Primary CompletionAug 1, 2026
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 4.3 years agoPrimary completion in 29 days

Interventions

Intensity Modulated Radiation Therapy (IMRT)radiation

Participants will be treated with intensity modulated radiation therapy (IMRT) with photons, which is FDA (U.S. Food and Drug Administration) approved radiation delivery system.

MRIother

Participants will receive pretreatment diagnostic MRIs to generate MRI habitats. These images will identify radioresistant cells within tumor.